Of course I'm not certain about the trials failing, or succeeding, for that matter. What is inevitable is that the market will come to realize that a preclinical-stage company focused on a single indication with a market size of maybe 200MM with a bumbling fool of a CEO is not worth $150MM and you'll all go down to $0.25 pps. Look at comps. Someone provide me their idea of a comp biotech so we can engage in a conversation on valuation. No one will do that. Anyone? Anyone?
Some major investment company just invested $20 million into the company at $2.10 that is a market cap of around $130 million....seems they believe this company is worth it!! We will find out which company bought those 10 million shares during the trials!